1-10 of 31 results
Item icon
mg, and 250 mg dosages of NUVIGIL®. The settlements allow Actavis to launch generic … 50 mg, 150 mg, and 250 mg NUVIGIL® under license beginning in June 2016, or earlier …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1940346View duplicates

Item icon
TEVA Investor Relations - Teva Reports Second Quarter 2012 Results … The National Network of Excellence in Neuroscience (NNE) … Net Revenues Total $5.0 Billion, up 19% …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1721484View duplicates

Item icon
The National Network of Excellence in Neuroscience (NNE) … Fourth Quarter 2012 Net Revenues of $5.2 Billion and Full Year Net Revenues of $20.3 Billion … Cash Flow from Operations of $1.6 …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1782674View duplicates

Web Page
Teva Products - To achieve our vision to become the most indispensable medicines company in the … of the symptoms of Parkinson's disease and NUVIGIL® for the treatment of sleep disorders. …
Size: 72KB

http://www.tevapharm.com/products

Item icon
TEVA Investor Relations - Teva Reports Second Quarter 2014 Results … The National Network of Excellence in Neuroscience (NNE) … Revenues of $5.0 billion, up 2% compared to the second …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1953508View duplicates

Item icon
continue to focus on our current NUVIGIL® indications and we remain committed to … insomnia. Full prescribing information for NUVIGIL® is available at www.NUVIGIL.com. …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1851019View duplicates

Item icon
Final Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated … Phase III clinical study for armodafinil (NUVIGIL®) as adjunct therapy in adults with …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsclinical&nyo=2View duplicates

Item icon
TEVA Investor Relations - Teva Reports Third Quarter 2012 Results … The National Network of Excellence in Neuroscience (NNE) … Net Revenues Total $5.0 Billion, up 14% …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1752738View duplicates

Item icon
TEVA Investor Relations - Teva Reports Third Quarter 2013 Results … The National Network of Excellence in Neuroscience (NNE) … Non-GAAP EPS of $1.27, GAAP Diluted EPS of $0.84 …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1870794View duplicates

Item icon
TEVA Investor Relations - Teva Reports Second Quarter 2013 Results … The National Network of Excellence in Neuroscience (NNE) … Non-GAAP Diluted EPS of $1.20, GAAP Diluted EPS Loss of $0.53 …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1843483View duplicates